Overexpression of heme oxygenase-1 protects dopaminergic neurons against 1-methyl-4-phenylpyridinium-induced neurotoxicity
Journal
Molecular Pharmacology
Journal Volume
74
Journal Issue
6
Pages
1564-1575
Date Issued
2008
Author(s)
Abstract
Heme oxygenase-1 (HO-1) is up-regulated in response to oxidative stress and catalyzes the degradation of pro-oxidant heme to carbon monoxide (CO), iron, and bilirubin. Intense HO-1 immunostaining in the Parkinsonian brain is demonstrated, indicating that HO-1 may be involved in the pathogenesis of Parkinsonism. We here locally injected adenovirus containing human HO-1 gene (Ad-HO-1) into rat substantia nigra concomitantly with 1-methyl-4- phenylpyridinium (MPP+). Seven days after injection of MPP + and Ad-HO-1, the brain was isolated for immunostaining and for measurement of dopamine content and inflammatory cytokines. It was found that overexpression of HO-1 significantly increased the survival rate of dopaminergic neurons; reduced the production of tumor necrosis factor α (TNF-α) and interleukin-1β (IL-1β) in substantia nigra; antagonized the reduction of striatal dopamine content induced by MPP+; and also up-regulated brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) expression in substantia nigra. Apomorphine-induced rotation after MPP+ treatment was also inhibited by Ad-HO-1. On the other hand, inhibition of HO enzymatic activity by zinc protoporphyrin-IX facilitated the MPP+-induced rotatory behavior and enhanced the reduction of dopamine content. HO-1 overexpression also protected dopaminergic neurons against MPP+-induced neurotoxicity in midbrain neuron-glia cocultures. Overexpression of HO-1 increased the expression of BDNF and GDNF in astrocytes and BDNF in neurons. Our results indicate that HO-1 induction exerts neuroprotection both in vitro and in vivo. Pharmacological or genetic approaches targeting HO-1 may represent a promising and novel therapeutic strategy in treating Parkinsonism. Copyright ? 2008 The American Society for Pharmacology and Experimental Therapeutics.
SDGs
Other Subjects
1 methyl 4 phenylpyridinium; adenovirus vector; apomorphine; brain derived neurotrophic factor; dopamine; glial cell line derived neurotrophic factor; heme oxygenase 1; interleukin 1beta; protoporphyrin zinc; tumor necrosis factor alpha; animal cell; animal experiment; animal model; animal tissue; article; cell survival; circling behavior; controlled study; dopaminergic nerve cell; enzyme inhibition; gene; gene overexpression; ho 1 gene; immunohistochemistry; neuroprotection; neurotoxicity; nonhuman; parkinsonism; pathogenesis; priority journal; protein expression; rat; substantia nigra; 1-Methyl-4-phenylpyridinium; Adenoviridae; Animals; Brain-Derived Neurotrophic Factor; Cell Death; Cells, Cultured; Coculture Techniques; Dopamine; Enzyme Induction; Glial Cell Line-Derived Neurotrophic Factor; Heme Oxygenase-1; Humans; Interleukin-1beta; Neuroglia; Neurons; Parkinson Disease, Secondary; Rats; Rats, Wistar; RNA, Messenger; Tumor Necrosis Factor-alpha
Type
journal article